BSD Medical is Now Pyrexar Medical

The complete line of BSD Hyperthermia products are availble thru Pyrexar Medical

Change the OddsPublished last month in the International Journal of Hyperthermia, N. Datta, S.Rogers, S.G. Ordonez, E. Puric and S. Bodis review and analyze ~30 years of studies conducted to evaluate the outcome of controlled clinical trials in head and neck cancers (HNCs) using hyperthermia and radiotherapy versus radiotherapy alone.

The article titled “Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis” finds level 1 evidence of the efficacy of HTRT (Hyperthermia + Radiotherapy) over RT (Radiotherapy alone) in the treatment of Head and Neck Cancers.  

The most recent study in 2014 by Wen et provided data demonstrating that HT+RT was one and half times more effective than RT alone.  Of the six studies evaluated the benefit of Hyperthermia as an adjunct treatment had an overall benefit ratio of 1.6.

The evidence that Hyperthermia is a vital cancer treatment therapy continues to grow.  Adding heat to radiation therapy, chemotherapy, and immunotherapy shrinks tumors and increases sensitivity to traditional cancer therapies without adding toxicity.  Thermal Therapy Works!

Wall Street Journal Article

The Wall Street Journal just published an article on Hyperthermia’s resurgence in the medical scene. Although the report lacks to mention some of the fantastic results that this therapy produces in cervical, bladder, pancreatic, melanoma, ovarian, breast, esophageal, prostate, and head/neck cancers (to name a few), it at minimum brings hyperthermia back in the spotlight.  READ THE ARTICLE

The article mentions some studies in the ’90s where outcomes were not as stellar as they are today. This may be due to early lab built equipment, and inadequate protocols had much to do with that data. Today, with our BSD-500 Superficial/Interstitial and BSD-2000 Deep Regional systems at the center of many critical phase III medical trials, results can be 2 to 3 times greater when adding hyperthermia to chemotherapy and radiotherapy.

Immunology is the real story here. The body is an efficient cancer-fighting device. Heating the cancerous tumors to fever temperatures (42-42˚C) appears to unmask cancer from the body's immune system. We will see the results of this ongoing research and study of the immunological effect soon.

Resources: Fever and the thermal regulation of immunity: the immune system feels the heat; Sharon S. Evans, Elizabeth A. Repasky& Daniel T. Fisher

rsna outdoor flag

This year the Radiological Society of North America (RSNA) held in Chicago attracted an estimated 55,0000 medical professionals from around the world.  Wandering through the maze of displays by medical device manufacturers were an army of international distributors looking for something new.

“Something new” seemed to be the theme of the five-day event, and hyperthermia appeared to fit the bill.  The show provided a personal introduction and interaction platform that no brochure, website, or email can reproduce.  Key players from Europe, Asia, South America, and the Middle East passed through the booth to learn about the fantastic benefits that hyperthermia had to offer.

In addition to the wealth of business opportunities, medical and technical students had the chance to see and touch the equipment with which they may one day participate. As the only representative company for this particular therapy at the show, we felt great privilege in participating in the educational process.

Overall the show was a great success.  Some incredible business relationships were formed, and some big deals solidified. But you will need to wait a bit before we can reveal that news.

RSNA15 mapThis year the Radiological Society of North America (RSNA) will hold its annual meeting in Chicago, marking the organization's 100th anniversary.  The RSNA is the world's largest annual medical meeting, with attendance estimated at 55,000 people.  The five-day event includes two large exhibition halls presenting medical device products and a full schedule of presentations and education.  The program starts Sunday, Nov 29th, and runs through Thursday, Dec. 3rd.

Since this is a massive show, I have included a map Link to help you find us. Our booth, #6563, is located in the far end of North Building, Hall B, just past the end of the Philips booth and directly across from North Cafe.

In addition to our booth and sales team, you may be interested in a lecture by Mark Dewhirst, DVM, Ph.D. from Duke University Medical Center. "Lessons Learned from XRT/Hyperthermia | VISIO41-03” will discuss how hyperthermia compliments the ability of radiotherapy to kill cancer cells include a review of the more than a dozen positive phase III cancer trials; and provide new insights on how hyperthermia affects the process of DNA damage repair.

Lessons Learned from XRT/Hyperthermia
    Wednesday 1:55-2:10 PM | VSIO41-03 | S405AB

Mark W. Dewhirst, DVM, Ph.D. durham, NC (Presenter)
Stockholder, Celsion Corporation Research Grant, Biomimetix Corporation Research Grant, Johnson & Johnson Consultant, Nevro Corp Consultant, Merck KGaA Consultant, Siva Corporation

1) Understand the complementary interactions between hyperthermia and radiotherapy that increase cell killing. 2) Understand the importance of measuring temperature during heating and methods for how this is accomplished. 3) Be able to articulate how hyperthermia affects tumor physiology and how these effects influence treatment responses.

There are more than a dozen positive phase III trials showing that hyperthermia can increase local tumor control when it is combined with radiotherapy. Such trials include head and neck cancer, cervix cancer, GBM, esophageal cancer, and chest wall recurrences of breast cancer. It has been known for more than two decades that hyperthermia augments the cytotoxicity of radiotherapy. Basic tenants underlying this interaction include proof that hyperthermia inhibits DNA damage repair. Hyperthermia has complimentary cytotoxicity with radiation in different parts of the cell cycle.

Further, hyperthermia can increase tumor perfusion, thereby increasing oxygen delivery; lack of oxygen is a source of relative resistance to radiotherapy. In recent years, however, new insights have been made into how these two treatment modalities interact. These insights come from 1) innovative clinical trials involving functional imaging and genomics, and 2) examination of how hyperthermia affects the process of DNA damage repair. These developments point the way toward new methods to further therapeutic gain by taking advantage of cellular responses to these therapies.